Last updated on February 2018

Safety Evaluation of China Patients: Long-term Treatment Outcome of Conbercept Ophthalmic Injection in Real Word STONE


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Wet Age Related Macular Degeneration
  • Age: - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  1. The condition that informed consent has been freely given prior to research-related procedures;
  2. Patients who have received at least one intravitreal injection of Conbercept Ophthalmic Injection after informed consent has been given.

Exclusion Criteria:

  1. Patients who have been on any of other anti-VEGF drugs systematically or locally, including but not limited to bevacizumab, ranibizumab and aflibercept, 90 days before enrollment;
  2. Those who are on other study drugs or have been on other study drugs 30 before informed consent is given.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.